Skip to Content
Søg Menu

Trastuzumab Deruxtecan Show Maintenance of Overall Health Status and Quality of Life in Patients with HER2 Positive Metastatic Breast Cancers

DESTINY-Brest03 was a prospective randomized phase 3 clinical trial that aimed to compare the efficacy of trastuzumab deruxtecan (T-DXd) with that of trastuzumab emtansine (T-DM1) in patients suffering from HER2 positive metastatic breast cancers.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Frederik Baastrup

Implementering af AI i screening for brystkræft

/ Frederik Baastrup
AIDSKO24Brystcancer Play the Video 4:57

Consecutive Mammography Screening Is the Best Way to Reduce the Risk of Premature Death from Breast Cancer

/ Sofie Pohl
Brystcancer

Recent Updates in Breast Cancer Screening – A Norwegian Perspective

/ Kaitlyn Tsuruda / Solveig Hofvind
Brystcancer
László Tabár

Mammography Screening Is the Best Way to Reduce the Risk of a Premature Death from Breast Cancer

/ László Tabár
Brystcancer Play the Video 7:11

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

/ Sofie Pohl
ASCOGI24Gastrointestinal cancerBrystcancer
Hatem Azim

Using Fertility Options May be Safe for Patients with HR-positive Breast Cancer

/ Hatem Azim
SABCS23Brystcancer Play the Video 10:10
Terry Mamounas

The Effectiveness of Regional Nodal Radiation in Patients with Breastcancer

/ Eleftherios (Terry) P. Mamounas
SABCS23Brystcancer Play the Video 13:26

Endometriecancer: PD-L1 hæmmer i kombination med PARP-hæmmer reducerer signifikant progressionsfri overlevelse

/ Anja Ør Knudsen
ESMO23Brystcancer

SABCS 2023: HR-Positive Breast Cancer Patients May Safely Use Fertility Options

/ BestPractice Nordic
SABCS23Brystcancer

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top